Preemptive attack of Sanofi to launch Toujeo next month in novel basal insulin competition
Sanofi-Aventis has created a foundation to be a step ahead in the competition of a novel insulin against Novo Nordisk.
According to Sanofi, ‘Toujeo(generic name: insulin glargine),’ a next-generation once-daily long-acting basal insulin, will be launched with health insurance benefit from the 1s...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
